作者: Bicui Chen , Li Chen , Cai Cheng , Mingkang Zhong , Xiaojin Shi
DOI: 10.1002/BMC.4140
关键词:
摘要: Creatine kinase elevation is commonly reported in telbivudine-treated patients. However, little known about the relationship between this adverse drug reaction and plasma concentration. In study, a sensitive, rapid safe quantitative bioanalytical method has been established by using LC-MS/MS for determination of telbivudine clinical study chronic hepatitis B The assay was linear dynamic 10-10,000 ng/mL range (r2 > 0.999) total analysis time 6 min method. validated applied to quantitatively determine concentration patients during long-term treatment. results revealed that creatine kinase-elevated group (707.92-2788.78 ng/mL) significantly higher than those with normal (412.63-1108.32 ng/mL). This adapted therapeutic monitoring.